“…Vanholder et al ranked IS toxicity with the second highest evidence score in SPBMs, such as inflammation, CVD, CKD–MBD, fibrosis metabolic function, and thrombogenicity [ 28 ]. IS acts widely across various organs, tissues, and cells such as bones [ 29 , 30 , 31 , 32 , 33 ], skeletal muscles [ 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 ], and myocardium [ 45 , 46 , 47 , 48 , 49 , 50 , 51 ], causing dysfunction in their functions. A clinical study has shown that the serum levels of IS increased with CKD progression, and high levels of serum IS are independently associated with an increased all-cause mortality and cardiovascular mortality in CKD patients [ 25 ] and a trend towards increased cardiovascular events in hemodialysis patients [ 23 ].…”